Skip to content

Skipping Newborn Vitamin K Shots Raises Bleeding Risk, Study Finds

November 9, 2026
Doctor in scrubs holding a newborn baby beside hospital monitoring equipment

Medicine & Healthcare

By TrendScope Daily Team · November 9, 2026

Share WhatsApp Facebook X LinkedIn Copy Link

A newborn who does not get the routine vitamin K injection at birth is 47% more likely to bleed in the first six months of life than one who does, according to the largest study yet on the question. The research, published November 5, 2026 in JAMA, tracked more than 5.2 million infants born in the United States between 2017 and 2025, and it lands as more American parents are quietly declining a shot doctors have given almost every newborn since the 1960s.

What the study actually found

The team, led by Kristan Scott, MD, MSHP, of Children’s Hospital of Philadelphia, used electronic health record data from the Epic Cosmos network. After excluding infants born before 35 weeks and most home births, they were left with 5,240,780 babies. Of those, 234,825 — about 4.5% — did not receive the intramuscular (IM) vitamin K shot.

Among infants who skipped the shot, 288 per 10,000 had a bleeding event by six months, versus 185.9 per 10,000 among those who got it — an adjusted risk ratio of 1.47. The gap widened sharply for the most dangerous outcomes: intracranial bleeding occurred in 33 per 10,000 nonrecipients versus 13.2 per 10,000 recipients (more than double the risk), and death with bleeding during the birth hospitalization was nearly three times as likely. Researchers calculated that for every 114 babies who went without the shot, one extra bleeding event occurred that otherwise would not have.

A ten-year decline in coverage

The nonreceipt rate itself has been climbing: from 3.1% of births in 2017 to 6.8% in 2025, according to the study. A companion research letter in JAMA Pediatrics, using data from more than 11 million infants, found that diagnoses of vitamin K deficiency bleeding (VKDB) — the specific disorder the shot prevents — rose from 24.0 to 107.4 per 100,000 over the same period, as injectable vitamin K uptake slipped from 97.7% to 95.0%. Strikingly, only 19.2% of infants later diagnosed with VKDB had actually received the injection, underlining how even a small decline in coverage can show up as more preventable bleeding. A similar pattern turned up in Sweden, where a cohort of more than two million infants found comparable increases in both bleeding risk and intracranial bleeding specifically.

Why the shot exists in the first place

Newborns are born with very little vitamin K, a nutrient the liver needs to make several blood-clotting proteins, and breast milk supplies only small amounts in the early weeks. Without supplementation, a small number of infants develop VKDB, which can cause anything from minor bruising to sudden, severe bleeding inside the skull weeks after birth, often with no obvious warning sign. That risk is why a single IM dose at birth has been standard pediatric practice in the US since the American Academy of Pediatrics first recommended it, and why the broader conversation about infant and maternal nutrition in India has long treated the first days after delivery as a distinct, higher-stakes window than ordinary wellness advice.

“Communicating the risk of bleeding with vitamin K declination just got a little easier.”

— Laura R. Kair, MD, MAS, UC Davis School of Medicine, in an accompanying JAMA editorial

What it means beyond the US

The decline documented in the study is a largely American phenomenon, tied to a broader rise in parents opting out of routine newborn interventions. India has not reported a comparable slide: the Government of India’s operational guidelines make IM vitamin K prophylaxis a standard part of birth care in facilities nationwide, and with institutional delivery rates now well above 90% under government maternal-health programs, coverage has stayed high by design rather than by individual parental choice at the bedside. That gap is worth watching rather than ignoring — as home births and “natural birth” movements gain visibility on Indian social media, the same decision point could eventually arrive here too, which is exactly the kind of early warning an evidence base like this is meant to provide.

Dr. Kair and her co-authors, writing in the accompanying editorial, called for obstetricians, nurses and public health agencies to keep reinforcing the IM recommendation, for dedicated surveillance of who is and isn’t receiving the shot, and for a US Food and Drug Administration-regulated oral formulation for the small number of families who firmly decline the injection — a regulatory gap that doesn’t exist in countries, India included, where the injectable version remains near-universal practice. It’s a smaller, more technical story than a headline-grabbing FDA approval delay, but it shows the same pattern: regulators and researchers reacting to real-world data, not theory.

The limits of the data

The authors flagged several caveats. Infants born before 35 weeks and most home births were excluded, which likely understates true nonreceipt since birth centers are underrepresented in the dataset. Researchers could not always tell whether a baby who skipped the injection instead received an oral vitamin K alternative, and the data lacked detail on bleeding timing, severity or cause. There’s also a coding effect to consider: clinicians may be more inclined to document bleeding as notable when they already know vitamin K was declined, which could inflate the gap somewhat. None of that changes the direction of the finding, but it’s why the authors call for better surveillance rather than treating the numbers as final. For parents weighing newborn care decisions more broadly, the same evidence-first approach that applies to pregnancy weight gain applies here: large population studies like this one are what move clinical guidance, not anecdotes.

For families trying to separate evidence from anxiety in the newborn period, a plain-language reference written with pediatricians can help frame these conversations before they happen in a delivery room. Newborn care guidebooks that walk through routine birth interventions — vitamin K, the hepatitis B shot, hearing screens — are a reasonable starting point for first-time parents who want context ahead of the hospital’s own counseling.

Sources: Scott K, Handley SC, Lo JY, et al., “Nonreceipt of Newborn Vitamin K and Risk of Bleeding,” JAMA, Nov 5, 2026 · Contemporary Pediatrics coverage · American Academy of Pediatrics policy statement

Quick questions

Is the vitamin K shot mandatory for newborns?

In most of the US it is recommended but not legally mandatory, and parents can decline it, which is what this study measured. In India, it is a standard part of routine birth care under government guidelines and is given to nearly all babies born in a hospital or facility.

What is vitamin K deficiency bleeding (VKDB)?

VKDB is a bleeding disorder in newborns caused by low levels of vitamin K, which the body needs to produce clotting proteins. It can appear in the first week of life or, in a “late” form, anytime up to six months, sometimes as sudden and severe bleeding inside the skull.

Is there an oral alternative to the vitamin K injection?

Oral vitamin K regimens exist and are used in some countries, but researchers in this study note the US lacks an FDA-regulated oral formulation, and oral dosing generally requires multiple doses over weeks, making it easier to miss compared with a single injection at birth.

Related on TrendScope Daily


Bottom line

A single injection at birth cuts a newborn’s risk of serious bleeding by roughly a third, and the risk of intracranial bleeding by more than half, according to the largest dataset yet assembled on the question. The US trend of rising refusals is a reminder that routine, decades-old interventions still need active defending with current evidence — and a reminder, for a country like India where coverage already runs close to universal, of what’s actually being protected by keeping it that way.

This article is for general information and is not medical advice. Please consult a qualified doctor about your own health.

As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.

Share WhatsApp Facebook X LinkedIn Copy Link